Evidence map›Paper›PMID 39855201›Full record

ArticleCell2025

Designed mosaic nanoparticles enhance cross-reactive immune responses in mice.

Eric Wang, Alexander A Cohen, Luis F Caldera, Jennifer R Keeffe, Annie V Rorick, Yusuf M Adia, Priyanthi N P Gnanapragasam, Pamela J Bjorkman, Arup K Chakraborty

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Host Responses to SARS-CoV-2 with an Emphasis on Cytokines.International journal of molecular sciences · 2026
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Cross-reactive sarbecovirus antibodies induced by mosaic RBD nanoparticles.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Eric WangInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
Alexander A CohenDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Luis F CalderaDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Jennifer R KeeffeDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Annie V RorickDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Yusuf M AdiaDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Priyanthi N P GnanapragasamDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA. Electronic address: bjorkman@caltech.edu.
Arup K ChakrabortyInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139, USA. Electronic address: arupc@mit.edu.

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
The longevity and nature of the anti-SARS-CoV-2 cellular and humoral immune responsesP01AI165075 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D., BJORKMAN, PAMELA J · 2022 to 2023
$10.7M
Combinatorial and computational design of bnAb mRNA vaccines for HIVR61AI161805 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ANDERSON, DANIEL G · 2021 to 2023
$2.1M
Bill & Melinda Gates Foundation INV-034638NIAID NIH HHS P01 AI165075NIAID NIH HHS R61 AI161805NIAID NIH HHS U19 AI057229
6 · The paper itself

Abstract

Nanoparticle vaccines displaying combinations of SARS-like betacoronavirus (sarbecovirus) receptor-binding domains (RBDs) could protect against SARS-CoV-2 variants and spillover of zoonotic sarbecoviruses into humans. Using a computational approach, we designed variants of SARS-CoV-2 RBDs and selected 7 natural sarbecovirus RBDs, each predicted to fold properly and abrogate antibody responses to variable epitopes. RBDs were attached to 60-mer nanoparticles to make immunogens displaying two (mosaic-2

Indexed as

COVID-19COVID-19 VaccinesNanoparticlesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntibodies, NeutralizingAntibodies, ViralCross ReactionsEpitopesFemaleHumansMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesEpitopesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodycomputational methodsnanoparticleprotein designRBDsarbecovirusSARS-CoV-2vaccination

Identifiers

PMID39855201
PMCPMC11845252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.